Summary of Enovis Q4 2025 Earnings Call

1Key Financial Results and Metrics

Q4 2025 Performance:

Revenue: $576 million, up 3% year-over-year (2% organic growth).

Adjusted EBITDA Margin: 17.9%, flat year-over-year.

Adjusted EPS: $3.30, a 16% increase.

Free Cash Flow: $20 million, returning to positive after a negative 43% in the prior year.

Full Year 2025 Performance:

Total Revenue: $2.2 billion, representing 7% reported growth (6% organic growth).

Adjusted Gross Margin: 61%, up 170 basis points.

Interest Expense: $35 million, down from $57 million in the previous year.

Leverage Ratio: Reduced to 3.1x.

2Strategic Updates and Business Highlights

Key Priorities: Focus on commercial execution, operational excellence, and financial discipline.

Portfolio Transformation: Significant progress in reshaping the portfolio, with a strong emphasis on innovation and cross-selling synergies.

Product Launches: Successful launches of the Nebula Stent and OrthoDrive Impactor, with expectations for continued growth in extremities.

Innovation Pipeline: 50% more 510(k) clearances than previous years, with a robust pipeline of new products planned for the next 24 months.

One Enovis Initiative: Aiming for improved collaboration and efficiency across business units to enhance performance.

3Forward Guidance and Outlook

2026 Revenue Guidance: Expected to be between $2.31 billion and $2.37 billion, with mid-single-digit organic growth (4% to 6%).

Adjusted EBITDA Guidance: Projected range of $425 million to $435 million, indicating a 50 basis point margin improvement.

Free Cash Flow Conversion: Targeting over 25% in 2026, with a pathway to 70% to 80% in subsequent years.

4Bad News, Challenges, or Points of Concern

Goodwill Impairment: A noncash impairment of $501 million was recorded due to stock price evaluation, although it does not impact liquidity or cash flows.

Sales Day Impact: Q4 growth was negatively affected by 4 fewer selling days, which contributed to a lower-than-expected performance.

Market Dynamics: Concerns about potential headwinds from weather affecting elective procedures and competitive pressures in the orthopedic market.

Execution Risks: Acknowledgment of missed execution opportunities in Q4, indicating a need for improved commercial discipline.

5Notable Q&A Insights

Free Cash Flow Improvement: Management highlighted ongoing productivity projects and reduced integration costs as key drivers for anticipated cash flow improvements.

Arvis Rollout: The next-gen product is expected to launch in phases, with a flexible business model aimed at driving implant utilization.

Market Growth Expectations: The company anticipates continued above-market growth in the Recon segment, particularly in extremities and hips.

Portfolio Shaping: Management is focused on SKU rationalization and potential divestitures to enhance growth profiles and margins in the P&R segment.

Strategic Focus: Emphasis on improving commercial execution and leveraging synergies between Recon and P&R segments to drive overall performance. Overall, Enovis demonstrated resilience in a challenging operating environment, with a clear focus on growth and operational efficiency, while also acknowledging areas for improvement and potential market risks.